Updates in Drug-Related Pneumonitis Due to Targeted Oncologic Therapies

Abstract

An increasing number of newer targeted oncologic therapies approved for clinical use can cause drug-related pneumonitis. Drug-related pneumonitis can be difficult to diagnose and requires a high index of suspicion. This review serves as an update to a prior review in this journal about pneumonitis with precision oncology therapies. In this review, we focus on the incidence, timing of onset, and imaging patterns of pneumonitis associated with a number of newly approved precision oncologic agents, with a particular focus on new antibody-drug conjugate therapies.

Keywords

• pneumonitis
• precision oncology
• pulmonary adverse event
• antibody-drug conjugate